CONCLUSIONS: The results sh ow higher efficacy of ProMACE-CytaBOM regimen over CHOP regimen. ProMACE-CytaBOM regimen may prolong survival time of patients with moderately or highly maligna nt NHL.
CONCLUSIONS: The results sh ow higher efficacy of ProMACE-CytaBOM regimen over CHOP regimen. ProMACE-CytaBOM regimen may prolong survival time of patients with moderately or highly maligna nt NHL.
论:与CHOP方案相比,ProMACE鄄CytaBOM方案疗效较好,不良反应可以耐受,可作为治疗中、高度恶性NHL的?